Novartis reimagines medicine to improve and extend people’s lives using innovative science and technology to address some of society’s most challenging healthcare issues. They discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Glycopyrronium belongs to the class of medications called bronchodilators. This medication is used once daily for the long-term relief of symptoms such as shortness of breath and wheezing associated with the lung disease known as chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Glycopyrronium works by opening the airways to make breathing easier.